Tian T, Xu Y, Zhang X, et al. - Researchers assessed the relationship between pre-ablation stimulated thyroglobulin (ps-Tg) and persistent and recurrent disease in patients suffering from differentiated thyroid cancer (DTC). They also explored if incorporation of ps-Tg could offer a more individualized estimate of clinical results. They retrospectively analyzed 2524 DTC patients who had total thyroidectomy and radioiodine ablation between 2006 and 2018. Independent predictive factors for persistent/ recurrent disease, as revealed in multivariate analysis, included age, ATA risk stratification, M1, ps-Tg and cumulative administered activities. Integration of ps-Tg into ATA risk categories suggested that the existence of ps-Tg ≤ 10.1 ng/mL was related to a significantly reduced probability of having persistent/recurrent disease in intermediate- and high-risk patients. Among patients suffering from DTC, Ps-Tg (≤ 10.1 ng/mL) was revealed as a key predictor of clinical results. A more accurate prediction of clinical results could be achieved by incorporating it as a variable in the ATA risk stratification system.